Insulin Lispro (Humalog)

1. Overview

Insulin lispro is the first rapid-acting insulin analog ever developed, representing a landmark achievement in protein engineering that transformed diabetes management. Developed by Eli Lilly and Company and approved by the FDA on June 14, 1996, as Humalog, it was the first genetically engineered insulin analog to reach clinical use [1][2][14]. Insulin lispro demonstrated that rational modification of the human insulin sequence could overcome the pharmacokinetic limitations of regular insulin injections, enabling better mealtime glucose control and paving the way for all subsequent rapid-acting insulin analogs (insulin aspart, insulin glulisine).

The molecule is a 51-amino acid, two-chain peptide (A-chain: 21 amino acids; B-chain: 30 amino acids) with the molecular formula C257H383N65O77S6 and a molecular weight of approximately 5808 Da (CAS 133107-64-9) [14][16]. It differs from native human insulin by a single transposition: the order of lysine and proline at positions B28 and B29 is reversed, yielding Lys-B28/Pro-B29 (compared with Pro-B28/Lys-B29 in human insulin). This modification was directly inspired by the observation that insulin-like growth factor 1 (IGF-1) -- which has a proline-lysine (rather than lysine-proline) sequence in the analogous region -- does not self-associate into dimers. The transposition in lispro dramatically reduces monomer-monomer contacts at the B-chain C-terminus, destabilizing dimer formation and enabling rapid hexamer dissociation after subcutaneous injection [1][2][18].

A second-generation formulation, ultra-rapid lispro (marketed as Lyumjev, insulin lispro-aabc), was approved by the FDA on June 15, 2020. Lyumjev contains the same insulin lispro molecule with two additional excipients -- treprostinil (a prostacyclin analog that increases local vasodilation and vascular permeability) and citrate (which increases local vascular permeability) -- to further accelerate subcutaneous absorption [6][17][20]. Multiple biosimilar and follow-on products exist, including Admelog (insulin lispro, Sanofi, 2017) and authorized generics [12].

Over nearly three decades of clinical use, insulin lispro has accumulated one of the largest safety databases of any biopharmaceutical, with hundreds of millions of patient-years of exposure worldwide.

Molecular Weight

~5808 Da

Molecular Formula

C257H383N65O77S6

Structure

51 amino acids (A-chain 21 aa, B-chain 30 aa); two-chain disulfide-linked peptide

Key Modification

Transposition of Lys-B28 and Pro-B29 (positions reversed vs human insulin)

Onset of Action

15 min (Humalog); approximately 3 min earlier (Lyumjev)

Peak Effect

0.5-2.5 hours

Duration of Action

3-5 hours (shorter tail than regular insulin)

Bioavailability

~55-77% (subcutaneous, dose-dependent)

CAS Number

133107-64-9

Routes

Subcutaneous injection, IV infusion, CSII pump (approved)

FDA Status (Humalog)

Approved June 14, 1996 (first rapid-acting insulin analog)

FDA Status (Lyumjev)

Approved June 15, 2020 (ultra-rapid insulin lispro)

2. Mechanism of Action

Rational Design: The B28-B29 Transposition

The development of insulin lispro was grounded in the seminal protein engineering work of Brange et al. (1988), who systematically investigated the structural determinants of insulin self-association [1]. In the commercial formulation, insulin exists as zinc-stabilized hexamers, which provide chemical stability but create a pharmacokinetic barrier: after subcutaneous injection, hexamers must dissociate into dimers and then monomers before the approximately 5.8 kDa monomer can cross the fenestrated capillary endothelium for systemic absorption.

The key structural insight was that positions B28 and B29 are located at the dimer-forming interface of the insulin molecule [1][18]. In human insulin, Pro-B28 participates in critical beta-turn interactions and hydrophobic contacts that stabilize dimer formation. The Lys-B28/Pro-B29 transposition disrupts these contacts by: (1) removing the proline from the beta-turn position where it stabilizes dimer contacts; and (2) introducing the larger, charged lysine side chain at B28, which creates steric and electrostatic interference with the opposing monomer.

The result is a approximately 300-fold reduction in dimerization affinity while fully preserving insulin receptor binding affinity, since the B28-B29 region is not part of the receptor-binding surface (which involves primarily A1-A3, A19-A21, B12, B16, B24-B26) [1][15][18]. Metabolic potency, IGF-1 receptor binding, and mitogenic activity are all comparable to native human insulin [15].

Pharmacokinetics: Faster Absorption, Earlier Peak, Shorter Duration

After subcutaneous injection, insulin lispro hexamers dissociate into monomers within minutes, in contrast to the approximately 30-60 minutes required for regular human insulin [2][14]. Howey et al. (1994) demonstrated in the first-in-human euglycemic clamp study that insulin lispro achieved:

• Approximately 2-fold faster absorption rate
• Approximately 2-fold higher peak plasma concentration (approximately 60-80 microunits/mL versus approximately 30-40 microunits/mL)
• Peak concentration approximately 1 hour earlier (approximately 30-90 min versus approximately 120-180 min)
• Approximately 2-fold faster decline from peak, with a duration of action of 3-5 hours versus 6-8 hours for regular insulin [2]

This pharmacokinetic profile more closely resembles the physiological first-phase insulin response to food intake, enabling better matching of insulin action to postprandial glucose absorption.

Ultra-Rapid Lispro (Lyumjev) -- Enhanced Absorption

Lyumjev achieves further acceleration of insulin lispro absorption through two excipients [6][17][20]:

Treprostinil (1.18 mcg/100 units) is a prostacyclin analog that causes local vasodilation at the injection site, increasing subcutaneous blood flow and accelerating monomer absorption into the systemic circulation. Citrate (1.65 mg/100 units) increases local vascular permeability by a transcellular mechanism, further enhancing the rate of insulin transport across the capillary endothelium.

Together, these excipients produce approximately 3 minutes earlier appearance in plasma, approximately 75% greater insulin exposure in the first 15 minutes, and approximately 5 minutes earlier peak concentration compared with standard insulin lispro [20]. The total bioavailability and overall glucose-lowering effect remain equivalent.

Insulin Receptor Signaling

Insulin lispro binds the insulin receptor with essentially identical affinity to native human insulin and activates the same downstream pathways: PI3K/Akt signaling (glucose transport, glycogen synthesis, suppression of gluconeogenesis) and Ras/MAPK signaling (cell growth and differentiation). The Lys-B28/Pro-B29 transposition does not alter receptor binding kinetics, metabolic potency, or mitogenic activity [15].

3. Researched Applications

Mealtime Glycemic Control in Type 1 Diabetes (Strong Evidence -- FDA Approved)

The pivotal Phase 3 trial by Anderson et al. (1997) randomized 1,008 adults with type 1 diabetes in a 6-month crossover design comparing insulin lispro with regular human insulin at mealtimes, both with NPH or ultralente basal insulin [3]. Insulin lispro reduced postprandial glucose excursions by approximately 30% compared with regular insulin, with a modest but statistically significant HbA1c improvement (-0.13%, p=0.04). Nocturnal hypoglycemia was reduced, and patient preference strongly favored lispro due to the ability to inject immediately before meals rather than the 30-minute pre-meal injection window required for regular insulin [3].

Type 2 Diabetes (Strong Evidence -- FDA Approved)

Anderson et al. (1997) also conducted a 12-month multinational trial in 722 adults with type 2 diabetes, demonstrating superior postprandial glucose control with insulin lispro versus regular insulin, comparable overall HbA1c, and fewer nocturnal hypoglycemia episodes [4]. These findings established insulin lispro for use across both type 1 and type 2 diabetes.

Premixed Formulations (Strong Evidence -- FDA Approved)

Premixed insulin lispro formulations -- Humalog Mix 75/25 (75% insulin lispro protamine suspension, 25% insulin lispro solution) and Humalog Mix 50/50 -- provide both prandial and basal insulin coverage in a single injection. Roach et al. (1999) demonstrated that Humalog Mix 75/25 provided significantly better postprandial glucose control than conventional human insulin 70/30, with comparable HbA1c and hypoglycemia [5].

Pregnancy (Moderate Evidence)

Insulin lispro is widely used during pregnancy despite initial FDA Category B designation. Wyatt et al. (2005) retrospectively analyzed 500 pregnancies in women with diabetes treated with insulin lispro or regular human insulin and found comparable maternal and neonatal outcomes with no teratogenic signal [9]. Better postprandial glucose control and higher patient satisfaction were noted with lispro. While large prospective trials like those conducted for insulin aspart (Mathiesen et al.) are lacking for lispro, the extensive observational data over 30 years and mechanistic similarity to human insulin provide strong reassurance.

Ultra-Rapid Lispro (Lyumjev) -- The PRONTO Program

The faster formulation was evaluated in the PRONTO clinical trial program:

PRONTO-T1D (n=1,222, type 1 diabetes) demonstrated that ultra-rapid lispro was noninferior to standard lispro for HbA1c control, with statistically superior 1-hour postprandial glucose reduction (ETD -15.4 mg/dL, p less than 0.001) and 2-hour reduction (ETD -14.6 mg/dL, p less than 0.001) [6].

PRONTO-T2D (n=673, type 2 diabetes) confirmed noninferiority for overall glycemic control with superior postprandial glucose control at 1 and 2 hours [7].

PRONTO-Pump (n=49, type 1 diabetes on CSII) demonstrated comparable glycemic control with faster postprandial glucose-lowering onset and comparable infusion set survival [8].

Comparison with Other Rapid-Acting Analogs

Multiple systematic reviews and meta-analyses have compared insulin lispro, insulin aspart, and insulin glulisine [10][11]:

• Insulin lispro vs insulin aspart: Head-to-head studies show no clinically significant differences in HbA1c, postprandial glucose control, hypoglycemia rates, or patient satisfaction. The analogs are considered clinically interchangeable [10]
• Insulin lispro vs insulin glulisine: Similarly equivalent in clinical studies
• Ultra-rapid formulations: Lyumjev (ultra-rapid lispro) and Fiasp (faster aspart) both provide approximately 3-5 minutes earlier onset and superior postprandial glucose control compared with their standard formulations. No head-to-head trials between Lyumjev and Fiasp have been published

A Cochrane systematic review by Siebenhofer et al. (2006) pooling 49 RCTs confirmed that rapid-acting analogs as a class modestly reduce HbA1c by approximately 0.1% versus regular human insulin, with meaningful postprandial glucose improvements and no increase in severe hypoglycemia [11].

CSII Pump Therapy (Strong Evidence)

Insulin lispro was the first rapid-acting analog widely adopted for CSII pump therapy and remains one of the most commonly used pump insulins. Its rapid absorption profile is particularly advantageous in pumps, where the absence of a subcutaneous hexamer depot means that mealtime boluses begin working within minutes. The reduced duration of action also provides better correction of hyperglycemia with bolus doses without stacking risk [14].

4. Clinical Evidence Summary

5. Dosing in Research

Type 1 Diabetes (Humalog). Insulin lispro should be injected subcutaneously within 15 minutes before or immediately after meals as part of a basal-bolus regimen. The mealtime dose is individualized using carbohydrate counting (typically 1 unit per 10-15 grams of carbohydrate), with correction doses based on insulin sensitivity factor [16]. Total daily insulin is typically divided with approximately 40-50% as basal insulin (glargine, detemir, or degludec) and the remainder as lispro at meals.

Type 2 Diabetes (Humalog). Mealtime insulin lispro may be initiated at 4 units or approximately 10% of the basal dose at the largest meal, with titration by 1-2 units every 2-3 days to achieve postprandial glucose targets. Stepwise addition to additional meals as needed [16].

Lyumjev (Ultra-Rapid Lispro). Same unit dosing as standard lispro. May be injected at the start of the meal or within 20 minutes after starting the meal, providing greater dosing flexibility [17].

Premixed Formulations. Humalog Mix 75/25 and 50/50 are administered within 15 minutes before meals, typically twice daily (before breakfast and dinner). Doses are individualized to glycemic targets [16].

U-200 Concentration. Insulin lispro U-200 (200 units/mL) is bioequivalent to U-100 and delivers the same dose in half the volume, which is convenient for patients requiring higher mealtime doses [13].

Intravenous Use. Insulin lispro may be administered intravenously for diabetic ketoacidosis and perioperative glucose management [16].

6. Safety and Side Effects

The safety profile of insulin lispro is supported by nearly 30 years of clinical experience and one of the largest postmarketing safety databases for any biopharmaceutical.

Hypoglycemia is the most important adverse effect. The rapid onset and shorter duration of insulin lispro compared with regular human insulin may reduce late postprandial hypoglycemia but does not eliminate the risk. Nocturnal hypoglycemia rates are generally lower than with regular insulin in clinical trials [3][4]. As with all insulin therapy, the risk increases with sulfonylurea or additional insulin use, missed meals, exercise, and impaired renal or hepatic function.

Injection-site reactions include lipodystrophy with repeated use at the same site and occasional local erythema or pruritus. With Lyumjev, injection-site reactions are modestly more frequent due to the treprostinil and citrate excipients, which cause local vasodilation and may produce transient warmth, erythema, or discomfort at the injection site [6][17].

Weight gain is associated with insulin therapy in general and is not specific to insulin lispro.

Immunogenicity. Anti-insulin antibodies may develop but are rarely clinically significant. No differences in immunogenicity have been observed between insulin lispro and regular human insulin, or between reference Humalog and biosimilar Admelog [12].

Allergic reactions. Rare systemic reactions (anaphylaxis, generalized urticaria) have been reported.

Hypokalemia may occur, particularly with intravenous administration. Potassium monitoring is recommended.

Pregnancy safety. Extensive observational data and retrospective analyses support the safety of insulin lispro during pregnancy, with no teratogenic signal and outcomes comparable to regular human insulin [9].

Contraindications. Insulin lispro is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro or any excipient.

Drug interactions. Standard insulin interaction profile: increased hypoglycemia risk with sulfonylureas, ACE inhibitors, MAO inhibitors, fibrates, and salicylates; decreased glucose-lowering effect with corticosteroids, thiazide diuretics, sympathomimetics, and atypical antipsychotics.

7. Historical Significance

Insulin lispro holds a unique position in the history of biotechnology and diabetes therapeutics. It was the first protein-engineered insulin analog to receive regulatory approval, validating the concept that rational modifications to the insulin sequence could improve pharmacokinetic properties while preserving biological activity [1][14]. The success of lispro directly enabled the development of all subsequent rapid-acting analogs (insulin aspart, 2000; insulin glulisine, 2004) and demonstrated the pharmaceutical viability of protein engineering for therapeutic proteins more broadly.

The development pathway from Brange's structural studies (1988) to Howey's first-in-human study (1994) to FDA approval (1996) exemplified a structure-based drug design approach that was ahead of its time. The identification that positions B28-B29 controlled self-association without affecting receptor binding was a foundational insight that continues to inform insulin analog design [1][2][18].

8. Pharmacokinetics

The pharmacokinetic advantage of insulin lispro derives entirely from its approximately 300-fold reduction in dimerization affinity caused by the Lys-B28/Pro-B29 transposition, enabling rapid hexamer-to-monomer dissociation at the subcutaneous injection site [1][2][18].

Absorption. After subcutaneous injection, lispro hexamers dissociate into monomers within minutes. Onset of appearance in plasma is approximately 15 minutes (Humalog) or approximately 12 minutes (Lyumjev). Tmax is approximately 30-90 minutes versus 120-180 minutes for regular insulin. Lyumjev achieves approximately 75% greater insulin exposure in the first 15 minutes and approximately 5 minutes earlier peak than standard lispro through treprostinil-mediated vasodilation and citrate-enhanced vascular permeability [20]. Bioavailability is approximately 55-77% (subcutaneous, dose-dependent), with absorption fastest from abdominal injection sites [16].

Distribution. Volume of distribution is approximately 0.12-0.15 L/kg. Minimal plasma protein binding beyond insulin receptor interactions. Distribution primarily to extracellular fluid.

Metabolism. Degraded by insulin-degrading enzyme (IDE) in the liver (approximately 60%) and kidneys (approximately 35-40%), identical to native human insulin. No active metabolites are produced [16].

Elimination. Terminal half-life is approximately 1 hour (subcutaneous). Duration of glucose-lowering action is 3-5 hours, approximately half the duration of regular insulin (6-8 h). This shorter tail reduces late postprandial hypoglycemia risk and allows less dose stacking with correction boluses [2][14].

U-100 vs U-200 bioequivalence. Leohr et al. demonstrated that lispro U-200 is bioequivalent to U-100 in both exposure and glucose-lowering effect, unlike insulin glargine where U-100 and U-300 have distinct PK profiles. The two concentrations are interchangeable without dose adjustment [13].

Special populations. Pediatric patients have similar PK profiles. In renal impairment (eGFR less than 30 mL/min), reduced insulin clearance may prolong action and increase hypoglycemia risk. Hepatic impairment similarly reduces clearance. In pregnancy, insulin requirements vary by trimester.

9. Dose-Response Relationship

Carbohydrate ratio titration. Standard starting ratio is 1 unit per 10-15 g carbohydrate, identical to insulin aspart. Individual adjustment based on postprandial glucose monitoring at 1-2 hours post-meal. More insulin-resistant patients may require 1 unit per 5-8 g; insulin-sensitive patients 1 unit per 15-30 g [16].

Postprandial glucose dose-response. The pivotal Anderson trial demonstrated approximately 30% reduction in postprandial glucose excursions with lispro versus regular insulin across the dose range, with a modest but significant HbA1c improvement (-0.13%, p=0.04) [3]. The benefit is most pronounced when injection timing is suboptimal (injecting at mealtime rather than 30 minutes before), because lispro's rapid onset compensates for the lack of pre-meal lead time.

Lyumjev dose-response. At equivalent unit dosing to standard lispro, Lyumjev provides superior 1-hour postprandial glucose reduction (ETD -15.4 mg/dL in PRONTO-T1D, ETD comparable in PRONTO-T2D) [6][7]. The benefit is greatest at the first hour post-meal and diminishes by 4 hours, reflecting the earlier temporal shift in absorption rather than a difference in total glucose-lowering potency.

Correction factor. The "1800 rule" (1800 / total daily dose = expected glucose drop per unit in mg/dL) applies. Correction doses are added to carbohydrate-based boluses. The shorter duration of lispro versus regular insulin reduces the risk of dose stacking when corrections are given within 2-3 hours of a previous bolus [14].

Premixed formulations. Humalog Mix 75/25 provides a fixed ratio of basal and prandial coverage, with dose titration based on overall glycemic targets rather than individual meal-by-meal adjustment.

10. Comparative Effectiveness

Insulin lispro vs insulin aspart. The most extensively studied rapid-acting analog comparison. The Plank systematic review (2005) and Cochrane review (2006) confirm no clinically significant differences in HbA1c, postprandial glucose, hypoglycemia, or patient satisfaction. Both are considered clinically interchangeable [10][11].

Insulin lispro vs insulin glulisine. Head-to-head studies show equivalent efficacy. Glulisine has a zinc-free formulation that may provide marginally faster initial absorption in some studies, but no clinical outcome differences have been demonstrated.

Lyumjev vs Fiasp. No head-to-head trials published. Both ultra-rapid formulations use different excipient strategies to accelerate absorption (treprostinil plus citrate for Lyumjev; niacinamide for Fiasp). Phase 3 data suggest comparable postprandial glucose improvements: Lyumjev ETD -15.4 mg/dL in PRONTO-T1D versus Fiasp ETD -12.0 mg/dL in onset 1. Both have modestly higher injection-site reactions than their standard formulations. Cross-trial comparison is limited by differences in basal insulin backbone, patient populations, and study design.

Lispro vs regular human insulin. Lispro provides approximately 30% better postprandial glucose control, modest HbA1c improvement (-0.1 to -0.13%), greater dosing convenience (injection at mealtime vs 30 min before), and fewer nocturnal hypoglycemia episodes. Benefits are most apparent in T1D on intensive therapy [3][11].

Biosimilar equivalence. Admelog (SORELLA-1, n=507) demonstrated therapeutic equivalence to Humalog over 52 weeks with comparable safety, immunogenicity, and hypoglycemia profiles, supporting interchangeability [12].

11. Enhanced Safety Profile

Nearly 30 years of safety data. Insulin lispro has one of the largest postmarketing safety databases of any biopharmaceutical, with hundreds of millions of patient-years of exposure since 1996. This extensive experience provides a comprehensive understanding of its safety profile across diverse populations.

Hypoglycemia. The rapid onset and shorter duration (3-5 h vs 6-8 h for regular insulin) reduces late postprandial hypoglycemia, particularly the 3-6 hour post-meal window. Nocturnal hypoglycemia is lower than with regular insulin in clinical trials. Risk increases with sulfonylureas, missed meals, exercise, and renal/hepatic impairment [3][4].

Lyumjev injection-site reactions. Modestly higher than standard lispro due to treprostinil and citrate excipients causing local vasodilation. Typically manifest as transient warmth, erythema, or mild discomfort lasting minutes. Rarely require discontinuation [6][17].

Pregnancy safety. Extensive observational data over 30 years support safety during pregnancy with no teratogenic signal (Wyatt et al., 500 pregnancies). While insulin aspart has a larger prospective RCT (Mathiesen trial), lispro's decades of use and mechanistic identity to human insulin provide strong reassurance. Compatible with breastfeeding [9].

Pediatric use. FDA-approved for pediatric use in T1D. Widely used in children of all ages including toddlers. Pediatric dosing follows the same carbohydrate ratio and correction factor principles as adults, with typically higher insulin sensitivity requiring larger ratios (1 unit per 20-30 g in young children) [16].

Renal impairment. Reduced insulin clearance in advanced CKD (eGFR less than 30 mL/min) typically requires 25-50% dose reduction. More frequent glucose monitoring essential. No formal dose adjustment guidelines exist in labeling.

Immunogenicity. Anti-insulin antibody development is comparable to regular human insulin and between reference Humalog and biosimilar Admelog. Clinically significant antibodies are rare [12].

Drug interactions. Standard insulin interaction profile: increased hypoglycemia risk with sulfonylureas, ACE inhibitors, MAO inhibitors, fibrates, salicylates. Reduced glucose-lowering with corticosteroids, thiazides, sympathomimetics, atypical antipsychotics. Beta-blockers may mask hypoglycemia symptoms [16].

CSII pump safety. Confirmed suitable for pump use. Infusion set survival is comparable between lispro and ultra-rapid lispro (PRONTO-Pump). Standard recommendation is infusion set change every 48-72 hours [8].

12. Related Peptides

See also: Insulin Aspart (NovoRapid / NovoLog), Insulin Glargine (Lantus / Toujeo), Insulin Degludec (Tresiba), Pramlintide (Symlin), Semaglutide (Ozempic / Wegovy)

13. References

1. [1] Brange J, Ribel U, Hansen JF, et al. (1988). Monomeric insulins obtained by protein engineering and their medical implications. Nature. DOI PubMed
2. [2] Howey DC, Bowsher RR, Brunelle RL, et al. (1994). [Lys(B28), Pro(B29)]-human insulin -- a rapidly absorbed analogue of human insulin. Diabetes. DOI PubMed
3. [3] Anderson JH Jr, Brunelle RL, Keohane P, et al. (1997). Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with type 1 diabetes. Arch Intern Med. DOI PubMed
4. [4] Anderson JH Jr, Brunelle RL, Koivisto VA, et al. (1997). Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther. DOI PubMed
5. [5] Roach P, Yue L, Arora V, et al. (1999). Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care. DOI PubMed
6. [6] Klaff LJ, Cao D, Engel SS, et al. (2020). Ultra rapid lispro (URLi) improves postprandial glucose control compared with lispro in patients with type 1 diabetes -- results from the PRONTO-T1D trial. Diabetes Care. DOI PubMed
7. [7] Blevins T, Zhang Q, Frias JP, et al. (2020). Ultra rapid lispro improves postprandial glucose excursions versus lispro in patients with type 2 diabetes (PRONTO-T2D). Diabetes Care. DOI PubMed
8. [8] Bode BW, Johnson JA, Hyveled L, et al. (2021). Ultra rapid lispro (URLi) in continuous subcutaneous insulin infusion -- PRONTO-Pump study. Diabetes Technol Ther. DOI PubMed
9. [9] Wyatt JW, Frias JL, Hoyme HE, et al. (2005). Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med. DOI PubMed
10. [10] Plank J, Siebenhofer A, Berghold A, et al. (2005). Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. DOI PubMed
11. [11] Siebenhofer A, Plank J, Berghold A, et al. (2006). Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus (Cochrane Review). Cochrane Database Syst Rev. DOI PubMed
12. [12] Garg SK, Engel SS, Engel M, et al. (2018). Efficacy, safety, and immunogenicity of biosimilar insulin lispro SAR342434 versus Humalog in adults with type 1 diabetes (SORELLA-1). Diabetes Technol Ther. DOI PubMed
13. [13] Leohr J, Deng H, Engel SS, et al. (2017). Insulin lispro U-200 is bioequivalent to insulin lispro U-100 in patients with type 1 diabetes. Diabetes Obes Metab. DOI PubMed
14. [14] Hirsch IB. (2005). Insulin analogues. N Engl J Med. DOI PubMed
15. [15] Kurtzhals P, Schaffer L, Sorensen A, et al. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. DOI PubMed
16. [16] Eli Lilly and Company. (2023). Humalog (insulin lispro injection) -- FDA prescribing information. FDA Label. PubMed
17. [17] Eli Lilly and Company. (2023). Lyumjev (insulin lispro-aabc injection) -- FDA prescribing information. FDA Label. PubMed
18. [18] DeFelippis MR, Chance RE, Frank BH. (2001). Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carrier Syst. DOI PubMed
19. [19] Heinemann L, Home PD, Hompesch M. (2019). Differentiating basal insulin preparations -- understanding how they work explains why they are different. Adv Ther. DOI PubMed
20. [20] Heise T, Linnebjerg H, Cao D, et al. (2020). Ultra rapid lispro (URLi) lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogs. Diabetes Obes Metab. DOI PubMed